Natural antibodies and cancer

Journal of Autoimmunity

Volumn 29, Issue 4, 2007, Pages 295-302

  Vollmers, H Peter ^a   Brändlein, Stephanie ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Autoimmunity; Cancer; Immune surveillance; Natural IgM antibodies

Indexed keywords

AUTOANTIBODY; CANCER ANTIBODY; CARBOHYDRATE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PAM 1; MONOCLONAL ANTIBODY SAM 6; MONOCLONAL ANTIBODY SC 1; UNCLASSIFIED DRUG;

ANTIBODY ISOLATION; APOPTOSIS; AUTOIMMUNITY; CANCER; CANCER CELL; GENE; GERM LINE; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; TUMOR IMMUNITY;

EID: 35448960028     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2007.07.013     Document Type: Review

References (68)

1. Abbas A., Lohr J., and Knoechel B. Balancing autoaggressive and protective T cell responses. J Autoimmun 28 (2007) 59-61
2. Ansari A., Pereira L.E., Mayne A.E., Onlamoon N., Pattanapanyasat K., Mori K., et al. The role of disease stage, plasma viral load and regulatory T cells (Tregs) on autoantibody production in SIV-infected non-human primates. J Autoimmun 28 (2007) 152-159
3. Youinou P. B cell conducts the lymphocyte orchestra. J Autoimmun 28 (2007) 143-151
4. Koike T., Bohgaki M., Amengual O., and Atsumi T. Antiphospholipid antibodies: Lessons from the bench. J Autoimmun 28 (2007) 129-133
5. Aoki C., Roifman C.M., Lian Z.X., Bowlus C.L., Norman G.L., Shoenfeld Y., et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 27 (2006) 50-53
6. Nurnberger T., Brunner F., Kemmerling B., and Piater L. Innate immunity in plants and animals: striking similarities and obvious differences. Immunol Rev 198 (2004) 249-266
7. Du Pasquier L. Innate immunity in early chordates and the appearance of adaptive immunity. C R Biol 327 6 (2004) 591-601
8. Bohn J. Are natural antibodies involved in tumour defence?. Immunol Lett 69 3 (1999) 317-320
9. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 37 18 (2000) 1141-1149
10. Martin F., and Kearney J.F. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 13 2 (2001) 195-201
11. Parkin J., and Cohen B. An overview of the immune system. Lancet 357 9270 (2001) 1777-1789
12. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 195 3 (2002) F9-F14
13. Viau M., and Zouali M. B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol 114 1 (2005) 17-26
14. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 1 2 (2001) 135-145
15. Pasare C., and Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 560 (2005) 11-18
16. Janeway C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54 Pt 1 (1989) 1-13
17. Medzhitov R., and Janeway Jr. C. The Toll receptor family and microbial recognition. Trends Microbiol 8 10 (2000) 452-456
18. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 (2002) 197-216
19. Schatz D.G., Oettinger M.A., and Schlissel M.S. V(D)J recombination: molecular biology and regulation. Annu Rev Immunol 10 (1992) 359-383
20. Gellert M. Recent advances in understanding V(D)J recombination. Adv Immunol 64 (1997) 39-64
21. Papavasiliou F., Jankovic M., Gong S., and Nussenzweig M.C. Control of immunoglobulin gene rearrangements in developing B cells. Curr Opin Immunol 9 2 (1997) 233-238
22. Rothenberg E.V. Stepwise specification of lymphocyte developmental lineages. Curr Opin Genet Dev 10 4 (2000) 370-379
23. Milner E.C., Anolik J., Cappione A., and Sanz I. Human innate B cells: a link between host defense and autoimmunity?. Springer Semin Immunopathol 26 4 (2005) 433-452
24. Brigl M., and Brenner M.B. CD1: antigen presentation and T cell function. Annu Rev Immunol 22 (2004) 817-890
25. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 10 (2004) 987-995
26. Klein J. Private and public antigens of the mouse H-2 system. Nature 229 5287 (1971) 635-637
27. Zinkernagel R.M., and Doherty P.C. The discovery of MHC restriction. Immunol Today 18 1 (1997) 14-17
28. Ehrlich P. The general significance of the side-chain theory, and its importance in biology and therapy. Spec Pathol Ther 8 (1900) 163-185
29. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 12 5 (1991) 154-159
30. Coutinho A., Kazatchkine M.D., and Avrameas S. Natural autoantibodies. Curr Opin Immunol 7 6 (1995) 812-818
31. Casali P., and Schettino E.W. Structure and function of natural antibodies. Curr Top Microbiol Immunol 210 (1996) 167-179
32. Baumgarth N., Tung J.W., and Herzenberg L.A. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 26 4 (2005) 347-362
33. Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer 7 3 (2007) 213-221
34. Ochsenbein A.F., Fehr T., Lutz C., Suter M., Brombacher F., Hengartner H., et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286 5447 (1999) 2156-2159
35. Brandlein S., Pohle T., Ruoff N., Wozniak E., Muller-Hermelink H.K., and Vollmers H.P. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 63 22 (2003) 7995-8005
36. Brandlein S., Beyer I., Eck M., Bernhardt W., Hensel F., Konrad H., et al. Cysteine-rich fibroblast growth factor receptor 1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res 63 9 (2003) 2052-2061
37. Brandlein S., Eck M., Strobel P., Wozniak E., Müller-Hermelink H.K., Hensel F., et al. PAM-1, a natural human IgM antibody as new tool for detection of breast and prostate precursors. Hum Antibodies 13 4 (2004) 97-104
38. Vollmers H.P., and Brandlein S. The "early birds": natural IgM antibodies and immune surveillance. Histol Histopathol 20 3 (2005) 927-937
39. Vollmers H.P., and Brandlein S. Death by stress: natural IgM-induced apoptosis. Methods Find Exp Clin Pharmacol 27 3 (2005) 185-191
40. Hensel F., Hermann R., Schubert C., Abé N., Schmidt K., Franke A., et al. Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res 59 20 (1999) 5299-5306
41. Hensel F., Brandlein S., Eck M., Schmidt K., Krenn V., Kloetzer A., et al. A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab Invest 81 8 (2001) 1097-1108
42. Rauschert SB, Holzinger E, Hensel F, Müller-Hermelink HK, Vollmers HP. A new variant of the heat shock protein GRP78 as target for the human lipotoxic antibody SAM-6, submitted for publication.
43. Livingston P.O., Wong G.Y., Adluri S., Tao Y., Padavan M., Parente R., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12 5 (1994) 1036-1044
44. Le Pendu J., Marionneau S., Cailleau-Thomas A., Rocher J., Le Moullac-Vaidye B., and Clement M. ABH and Lewis histo-blood group antigens in cancer. Apmis 109 1 (2001) 9-31
45. Macario A.J., and Conway de Macario E. Sick chaperones, cellular stress, and disease. N Engl J Med 353 14 (2005) 1489-1501
46. Ma Y., and Hendershot L.M. The role of the unfolded protein response in tumour development: friend or foe?. Nat Rev Cancer 4 12 (2004) 966-977
47. Li J., and Lee A.S. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 6 1 (2006) 45-54
48. Suriano R., Ghosh S.K., Ashok B.T., Mittelman A., Chen Y., Banerjee A., et al. Differences in glycosylation patterns of heat shock protein, gp96: implications for prostate cancer prevention. Cancer Res 65 14 (2005) 6466-6475
49. Pohle T., Brandlein S., Ruoff N., Muller-Hermelink H.K., and Vollmers H.P. Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res 64 11 (2004) 3900-3906
50. Brändlein S., Rauschert N., Rasche N., Dreykluft A., Hensel F., Conzelmann E., et al. The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized LDL. Mol Cancer Ther 6 1 (2007) 326-333
51. Vollmers H.P., O'Connor R., Muller J., Kirchner T., and Muller-Hermelink H.K. SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 49 9 (1989) 2471-2476
52. Hensel F., Hermann R., Brandlein S., Krenn V., Schmausser B., Geis S., et al. Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab Invest 81 11 (2001) 1553-1563
53. Mikesch J.H., Schier K., Roetger A., Simon R., Buerger H., and Brandt B. The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol 28 5-6 (2006) 223-232
54. Vollmers H.P., Zimmermann U., Krenn V., Timmermann W., Illert B., Hensel F., et al. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 5 3 (1998) 549-552
55. Brandlein S., Pohle T., Vollmers C., Wozniak E., Ruoff N., Muller-Hermelink, et al. CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep 11 4 (2004) 777-784
56. Zhou Z.-H., Tzioufas A.G., and Notkins A.L. Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun 29 (2007) 219-228
57. Ruiz-Argüelles A., Brito G.J., Reyes-Izquierdo P., Pérez-Romano B., and Sánchez-Sosa S. Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun 29 (2007) 281-286
58. Zelenay S., Fontes M.F.M., Fesel C., Demengeot J., and Coutinho A. Physiopathology of natural auto-antibodies: the case for regulation. J Autoimmun 29 (2007) 229-235
59. Papadimitraki E., Bertsias G., and Boumpas D.T. Toll like receptors and autoimmunity: a critical appraisal. J Autoimmun 29 (2007) 310-318
60. Lutz H. Homeostatic roles of naturally occurring antibodies. An overview. J Autoimmun 29 (2007) 287-294
61. Cohen I.R. Biomarkers, self-antigens and the immunological homunculus. J Autoimmun 29 (2007) 246-249
62. Pasquali J.-L., Soulas-Sprauel P., Korganow A.-S., and Martin T. Auto-reactive B cells in transgenic mice. J Autoimmun 29 (2007) 250-256
63. Lang K., Burow A., Kurrer M., Lang P., and Recher M. The role of the innate immune response in autoimmune disease. J Autoimmun 29 (2007) 206-212
64. Peng Y.F., Martin D.A., Kenkel J., Zhang K., Ogden C.A., and Elkon K.B. Innate and adaptive immune response to apoptotic cells. J Autoimmun 29 (2007) 303-309
65. Rowley B., Tang L., Shinton S., Hayakawa K., and Hardy R.R. Autoreactive B-1 B cells: constraints on natural autoantibody B cell antigen receptors. J Autoimmun 29 (2007) 236-245
66. Ryan K., Patel S.D., Stephens L.A., and Anderton S.M. Death, adaptation and regulation: the three pillars of immune tolerance restrict the risk of autoimmune disease caused by molecular mimicry. J Autoimmun 29 (2007) 262-271
67. Milner J., Ward J., Keane-Myers A., Min B., and Paul W.E. Repertoire-dependent immunopathology. J Autoimmun 29 (2007) 257-261
68. Lan R., Mackay I.R., and Gershwin M.E. Regulatory T cells in the prevention of mucosal inflammatory diseases: patrolling the border. J Autoimmun 29 (2007) 272-280